AAP
PLX icon

Arax Advisory Partners’s Protalix BioTherapeutics PLX Stock Holding History

Arax Advisory Partners’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$120 Buy
55
+16
+41% +$40 ﹤0.01% 3596
2025
Q4 		$71 Sell
39
-257
-87% -$525 ﹤0.01% 3877
2025
Q3 		$658 Buy
+296
New +$482 ﹤0.01% 3337
2025
Q1 		– Sell
-39
Closed -$74 – 2958
2024
Q4 		$74 Hold
39
– – ﹤0.01% 2401
2024
Q3 		$40 Hold
39
– – ﹤0.01% 2592
2024
Q2 		$46 Buy
+39
New +$46 ﹤0.01% 2516

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Arax Advisory Partners's PLX Position: Q1 2026 in Review

Arax Advisory Partners increased its Protalix BioTherapeutics (PLX) stake by 41% in Q1 2026, buying an estimated $40 and bringing the position to 55 shares worth $120. The position accounts for ﹤0.01% of the portfolio, ranked #3596.

Arax Advisory Partners first reported a position in PLX in Q2 2024 and has held it in 6 quarters since. The position peaked at $658 in Q3 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • Arax Advisory Partners held 55 shares of Protalix BioTherapeutics worth $120 as of Q1 2026.
  • Arax Advisory Partners bought 16 Protalix BioTherapeutics shares in Q1 2026, an estimated $40.
  • Protalix BioTherapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3596 holding.
  • Arax Advisory Partners first reported a position in Protalix BioTherapeutics in Q2 2024 and has held it in 6 quarters since.
  • Arax Advisory Partners's Protalix BioTherapeutics position peaked at $658 in Q3 2025.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.